University of Washington: Prostatic Neoplasms trials

The registry lists 37 Prostatic Neoplasms studies with University of Washington as lead sponsor. 7 are open to participants now and 16 have results posted.

Phase 1 4Phase 2 26No phase 10(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO TrialRecruitingNCT07698535Phase 2
• Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing DiseaseRecruitingNCT06526299Phase 2
• Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA StudyRecruitingNCT06039371Phase 2
• Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate CancerRecruitingNCT04489719
• Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL StudyRecruitingNCT04472338
• Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial CancerRecruitingNCT01050504
• Prostate Active Surveillance StudyRecruitingNCT00756665
• Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP StudyTerminatedNCT05960578Phase 2Results posted
• Olaparib for the Treatment of Castration Resistant Prostate AdenocarcinomaTerminatedNCT04951492Phase 2Results posted
• Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate CancerTerminatedNCT03999515Phase 2Results posted
• Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate CancerTerminatedNCT03649841Phase 2Results posted
• Olaparib Before Surgery in Treating Participants With Localized Prostate CancerTerminatedNCT03570476Phase 2Results posted
• A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomyCompletedNCT02849990Phase 2Results posted
• Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 PathwayCompletedNCT02598895Phase 2Results posted
• Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate CancerTerminatedNCT02565901Phase 1/2Results posted
• Degarelix Acetate Before and During Radiation Therapy in Treating Patients With Prostate CancerCompletedNCT01731912Not applicableResults posted
• Cabozantinib in Men With Castration-Resistant Prostate CancerTerminatedNCT01703065Phase 2Results posted
• Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate CancerCompletedNCT01503229Phase 2Results posted
• Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate CancerCompletedNCT01023061Phase 2Results posted
• Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate CancerCompletedNCT00466752Phase 2Results posted
• Maximal Suppression of the Androgen Axis in Clinically Localized Prostate CancerCompletedNCT00298155Phase 2Results posted
• Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate CancerCompletedNCT00283803Phase 2Results posted
• Effects of IAS in Men With Localized Biochemical Relapsed Prostate CancerCompletedNCT00223665Phase 2Results posted
• Buffered Lidocaine for Reducing Pain in Patients Undergoing Prostate Biopsy, BURN TrialCompletedNCT06661902Phase 1/2
• An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate CancerActive, not recruitingNCT04777071Phase 2
• Mechanisms of Metabolic and Hormone Action on Plaque Formation in Brain and Carotid Vessels in Patients With Prostate AdenocarcinomaTerminatedNCT03718338
• Genetic Testing for Men With Metastatic Prostate CancerTerminatedNCT03503097
• Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate CancerWithdrawnNCT02966587Phase 2
• Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate CancerCompletedNCT02532114Phase 1
• Carbon-11 Acetate and Fluorine F 18 Sodium Fluoride PET as a Biomarker of Treatment Response in Patients With Hormone Resistant Metastatic Prostate CancerWithdrawnNCT02169063Not applicable
• Study of Effectiveness of IMC-A12 Antibody Combined With Hormone Therapy Prior to Surgery to Treat Prostate CancerCompletedNCT00769795Phase 2
• Carbon-11 Acetate and Fludeoxyglucose F 18 PET Scan of the Bone in Patients With Metastatic Prostate Cancer That Has Spread to the BoneCompletedNCT00392938
• Immunotherapy After Chemotherapy for Patients With Hormone Refractory Metastatic Prostate CancerCompletedNCT00283829Phase 1/2
• Study of Aranesp to Treat Anemia in Prostate Cancer Patients.CompletedNCT00245895Phase 2
• Effects of ASA on Prostate TissueCompletedNCT00234299Not applicable
• Neoadjuvant Estradiol or Androgen Deprivation in Clinically Localized Prostate CancerCompletedNCT00167648Phase 2
• Docetaxel and Diethylstilbestrol in the Treatment of Androgen Independent Prostate CancerCompletedNCT00136526Phase 2